grant

Sex-dependent cardiac cyclic-AMP signaling and arrhythmias in the failing heart

Organization UNIVERSITY OF CALIFORNIA AT DAVISLocation DAVIS, UNITED STATESPosted 1 Jan 2024Deadline 31 Dec 2026
NIHUS FederalResearch GrantFY202521+ years old3'5'-cyclic ester of AMP3,5 cyclic AMP synthetaseAction PotentialsAddressAdenosine Cyclic 3',5'-MonophosphateAdenosine Cyclic MonophosphateAdenosine Cyclic Monophosphate-Dependent Protein KinasesAdenosine, cyclic 3',5'-(hydrogen phosphate)Adenyl CyclaseAdenylate CyclaseAdenylyl CyclaseAdrenergic AgentsAdrenergic DrugsAdrenergic beta-AntagonistsAdrenergic beta-BlockersAdrenergicsAdultAdult HumanAdvisory CommitteesAffectAnti-Arrhythmia AgentsAnti-Arrhythmia DrugsAnti-ArrhythmicsArrhythmiaAssayAwardBioassayBiochemicalBiological AssayCalciumCardiacCardiac ArrhythmiaCardiomyopathiesCardiovascular PhysiologyCatabolic Gene ActivatorsCatabolite Activator ProteinCatabolite Gene Activator ProteinsCatabolite Regulator ProteinsCause of DeathCell Communication and SignalingCell SignalingCessation of lifeChronicClosure by LigationCollaborationsCouplingCyclic AMPCyclic AMP Receptor ProteinCyclic AMP ReceptorsCyclic AMP-Dependent Protein KinasesDataDeathDifferences between sexesDiffers between sexesDysfunctionElectrophysiologyElectrophysiology (science)EnvironmentFRETFacultyFemaleFluorescence Resonance Energy TransferFunctional disorderFundingFörster Resonance Energy TransferGenderGene ExpressionGeneralized GrowthGenerationsGoalsGrowthHeartHeart ArrhythmiasHeart failureHeterogeneityImpairmentIncidenceIntracellular Communication and SignalingLeadLigationMapsMentorsMiceMice MammalsModelingMurineMusMuscle CellsMyocardial DiseasesMyocardial DisorderMyocardiopathiesMyocytesNeurophysiology / ElectrophysiologyOpticsOutcomeOutputPKAPathway interactionsPatientsPb elementPhasePhosphodiesterasesPhysiopathologyPositionPositioning AttributeProtein Kinase APublishingReceptor ActivationReporterResearchRiskRodent ModelRoleSex DifferencesSexual differencesSignal PathwaySignal TransductionSignal Transduction SystemsSignalingSurvival RateSystemTask ForcesTestingTherapeuticTimeTissue GrowthTrainingVentricular ArrhythmiaWomanadenosine 3'5' monophosphateadulthoodadvisory teamaorta constrictionarrhythmic agentbasebasesbeta blockerbeta-Adrenergic Blocking Agentsbeta-Adrenergic Receptor Blockadersbeta-adrenergic receptorbiological signal transductioncAMPcAMP Receptor ProteinscAMP ReceptorscAMP-Dependent Protein Kinasescardiac failurecardiac imagingcardiac scanningcardiovascular functioncomparing females and malescomparing women and mendesensitizationeffective therapyeffective treatmentelectrophysiologicalexperienceexperimentexperimental researchexperimental studyexperimentsextracellularfemales compared to malesfemales compared with malesfemales versus malesfemales vs. malesfunctional outcomesheart failure and reduced ejection fractionheart failure with reduced ejection fractionheart imagingheart scanningheavy metal Pbheavy metal leadimaging approachimaging based approachimaging systeminsightmalemenmultidisciplinarymyocardium diseasemyocardium disordernano meter scalenano meter sizednanometer scalenanometer sizednanoscalenew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachontogenyopticalpathophysiologypathwayphosphoric diester hydrolasepreservationpreventpreventingprogramsregional differenceresponsesexsex based differencessex-dependent differencessex-related differencessex-specific differencesskillssocial rolesuperresolution microscopytooltraining opportunitywomen compared to menwomen compared with menwomen versus menwomen vs. menβ-adrenergic receptor
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

PROJECT SUMMARY
Heart failure (HF) with reduced ejection fraction is a leading cause of death in the US. HF is associated with

autonomic dysregulation and significant remodeling of calcium handling, excitation-contraction coupling, and

electrophysiology, which collectively lead to contractile dysfunction and increased risk of ventricular arrhythmia.

HF incidence and outcomes are strongly sex-dependent; men have a higher incidence of HF, and in patients

with non-ischemic cardiomyopathy, women display a lower arrhythmia propensity than men. The precise

mechanisms underlying these sex differences and the protection in female hearts remain unclear.

Our initial studies discovered regional- and sex-dependent differences in b-adrenergic receptor (b-AR)- cyclic

AMP (cAMP) signaling that lead to previously unrecognized functional electrophysiological differences in male

and female mice, and could act as a potential anti-arrhythmic mechanism in female hearts. By combining whole-

heart, cellular, and subcellular approaches, this project aims to uncover novel mechanisms that underlie sex

differences in b-AR-cAMP signaling, which may play a role in sex-dependent outcomes in HF. A multi-level

experimental approach will be employed, investigating at the nanoscale, cellular, and whole heart level, to

examine: 1) the structural and functional mechanisms underlying sex differences in b-AR-cAMP signaling in the

intact heart, and 2) how sex- and region-dependent sympathetic remodeling in HF impacts b-AR-cAMP signaling

and arrhythmias. We propose to collaborate with a multidisciplinary advisory team to use novel whole-heart

FRET + optical mapping, isolated myocyte experiments, biochemical approaches, and super resolution

microscopy to assess cellular and subcellular mechanisms underlying regional- and sex-differences in b-AR-

cAMP signaling. How these signaling cascades and functional outputs are remodeled in a rodent model of HF

will also be tested. Completion of this proposal will significantly advance our understanding of sex differences in

cardiac patho-physiology and may provide insight into new gender-specific therapeutic approaches.

UC Davis offers an exceptional training environment for the mentored phase of the award to achieve these

goals. Moreover, the proposed research and training plan will significantly contribute to the applicant's personal

and professional growth. The mentored phase of this award will provide an invaluable training opportunity to

develop a unique scientific and professional skillset necessary to address the goals of this proposal, as well as

prepare for independence and make the applicant a competitive candidate for faculty positions. The independent

phase of this award will provide time, and funds, to create an independent research program in cardiovascular

physiology.

Grant Number: 5K99HL171836-02
NIH Institute/Center: NIH

Principal Investigator: Jessica Caldwell

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →